• Researcher Profile

    Bruce E. Johnson, MD

     
    Chief Clinical Research Officer
    Institute Physician


    Professor of Medicine, Harvard Medical School

    Center/Program

    Thoracic Oncology

    Office phone: 617-632-4790
    Fax: 617-632-5786

    Preferred contact method: office phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology/Solid Tumor Oncology

    Interests

    Non-small cell lung cancer, Small cell lung cancer, Genomic characterization, Mesothelioma

    Area of Research

    The impact of genomic changes on the targeted treatment of thoracic malignancies


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1234
    Boston, MA 02215

    Biography

    Dr. Johnson received his MD from the University of Minnesota in 1979 and his postgraduate training at the University of Chicago and the National Cancer Institute. After serving at NCI, where he most recently headed the Lung Cancer Biology Section, he joined DFCI in 1999. He currently leads the Dana-Farber/Harvard Cancer Center Lung Cancer Program and is the Chief Clinical Research Officer at the Dana-Farber Cancer Institute.

    Recent Awards

    • Member of the Association of American Physicians, 2015
    • Fellow of the American Society of Clinical Oncology, 2012
    • American Association for Cancer Research Team Science Award, 2010
    • International Association for Study of Lung Cancer Scientific Award, 2009
    • The ASCO Cancer Foundation Translational Research Professorship, 2008-2013

    Research

    The impact of genomic changes on the targeted treatment of thoracic malignancies

     My research is based on my multiple responsibilities as the leader of the Lung Cancer Program at the Harvard Medical School affiliated institutions. In my past role as Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, I have been responsible for fostering collaborative research across the clinical disciplines, integrating population and basic science into our research programs, and applying innovative therapeutic strategies into the treatment of our patients with lung cancer. I have led the Lung Cancer Program within the Dana-Farber/Harvard Cancer Center from a Program in Development to a full Program and was part of the successful Dana-Farber/ Harvard Cancer Center Grant competitive renewal in 2011 and received an exceptional rating. Under my leadership, the Lung Cancer Program has been able to increase its NIH funding 5 fold in the last 16 years. In addition, the Dana-Farber/Harvard Cancer Center Lung Cancer Program successfully renewed the Lung Cancer Specialized Program of Research Excellence Grant (SPORE) in 2008 and will submit the application in the fall 2016.   My translational research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies with specific genomic changes. I provide care in our Center for patients with thoracic malignancies one day per week. I also lecture widely on my research and treatment of patients with lung cancer.

    Members of our research group identified the link between mutations of the epidermal growth factor receptor and response to the epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib and erlotinib. Subsequent research has now changed the paradigm of treatment for patients with non-small cell lung cancer and sensitizing mutations of the epidermal growth factor receptor so the standard of care around the world is to get treated with erlotinib or gefitinib rather than chemotherapy. I am one of the patent holders of the test and now more than 50% of all the patients with nonsquamous non-small cell lung cancer get the test.  

    The systematic characterization of the genomic changes in lung cancer has now identified multiple changes that can lead to treatment with approved targeted agents (gefitinib and erlotinib) or enrollment onto ongoing investigation studies. These include EGFR, KRAS, HER2, BRAF, and PIK3CA mutations as well as the ALK and ROS1 rearrangements. I worked with members of our research group to set up systematic genomic characterization of nearly all of our advanced non-small cell lung cancer patients for EGFR, KRAS, HER2, BRAF, PI3KA mutations, ALK and ROS1 rearrangements, plus HER2 and MET amplification. We now characterize these genomic changes in 30-50 patients per month, track the results, are working toward placing them in the medical record, and preferentially steering these patients into appropriate genomically based protocols. It is our goal to treat a quarter of our patients with non-small cell lung cancer with targeted agents.

    Investigators

    • Jackman, David M., MD
    • Gandhi, Leena, MD, PhD

    Trainees

    • Ortiz, Taylor, MD
    • Heon, Stephanie, MD
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now